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During the past 12 years, many studies applying strict diagnostic criteria have been published that have attempted to settle
the controversy about the reality of the association between dermatomyositis and malignancy. Although retrospective,
recent studies have shown an increased incidence of malignancy among patients with dermatomyositis when compared
with controls without myositis. In contrast, an increased frequency of malignancy in dermatomyositis as compared to
polymyositis still has to be demonstrated. In most cases, malignant disease precedes or occurs concurrently with
dermatomyositis and is discovered on the basis of clinical signs, symptoms, and routine screening laboratory tests. The types
of neoplasms found in association with dermatomyositis parallel those observed in the general population. A possible link
between dermatomyositis and an underlying malignancy remains largely hypothetical at a biologic level, although cellular
immunity abnormalities may provide a direction for future investigations. Prospective epidemiologic studies using the case-
control methods and cohort analysis remain necessary 1) to rigorously demonstrate the reality and to study the nature of the
association between dermatomyositis and malignancy, and 2) to clarify the optimal screening strategies for malignant
neoplasms in patients with dermatomyositis. J Invest Dermatol 100:128S–132S, 1993
Dermatomyositis is a rare disease of unknown origin characterized
by symmetrical, proximal muscle weakness and specific skin lesions.
When the disease does not include characteristic cutaneous signs, it is
termed polymyositis. Conversely, some patients present with a typical
rash but without clinical or laboratory evidence of myopathy (this
problem is reviewed by Euwer and Sontheimer, p. 124S). In their well-
known paper published in 1975, Bohan and Peter [1] defined the five
diagnostic criteria of dermatomyositis as i) typical skin rash of
dermatomyositis; ii) proximal, symmetric muscle weakness; iii) elevation
of the serum muscle enzymes; iv) electromyographic features of
myopathy; and v) muscle biopsy evidence of an inflammatory myopathy.
They have also suggested confidence limits to assess the certainty of the
diagnosis (definite dermatomyositis, three or four criteria plus rash;
probable dermatomyositis, two criteria plus rash; possible dermatomyo-
sitis, one criterion plus rash) and a classification in five groups (group I,
adult polymyositis; group II, adult dermatomyositis; group III, dermato-
myositis/polymyositis associated with malignancy; group IV, juvenile
dermatomyositis/polymyositis [childhood dermatomyositis or dermato-
myositis associated with vasculitis]; group V, overlap group [dermato-
myositis or polymyositis with associated connective tissue disorder]),
which have been most widely used in further large published series,
allowing for comparative evaluation.
A link between dermatomyositis and internal malignancy has long
been suspected [2]. However, Bohan and Peter have questioned the
reality of this relationship using the analysis of 153 carefully defined
cases who fitted into the clinical spectrum of dermatomyositis and
polymyositis [3]. During the past ten years, numerous studies have been
published that have applied strict diagnostic criteria to identify patients
with dermatomyositis and polymyositis. Several of them have attempted
to determine the strength and nature of the link between dermatomyositis
and malignancy with partially conflicting results [4–17]. The purpose of
the present article is to critically review the literature on this topic and to
try to answer the following questions.
(1) Is there a really significant increase of cancer in patients with
dermatomyositis when compared to polymyositis and to an age- and
sex-matched general population, and what is the nature of this
association?
(2) How aggressive should the search be for malignancy in a patient
presenting with dermatomyositis?
(3) Is there a common biologic defect that can explain the concurrent
occurrence of both disorders?
THE REALITY AND THE NATURE OF THE ASSOCIATION
BETWEEN DERMATOMYOSITIS AND MALIGNANCY
Historical and Epidemiologic Aspects In 1916, Stertz [18] and Kankeleit
[19] reported the first cases of dermatomyositis associated with an
underlying malignancy (gastric carcinoma and breast cancer, respec-
tively). From 1916 to 1975, 258 similar cases have been published in the
literature whose data have been analyzed by Barnes [2]. This review
included only a few retrospective series from a single department or
institution and gave an overall frequency of malignancy associated with
dermatomyositis ranging from 7 to 34 per cent [20–22]. However, the
absence of a control group in these latter studies did not permit the
conclusion that there is a significantly increased risk of malignancy in
dermatomyositis. From these heterogeneous data, Barnes has concluded
that there might be an increased incidence of malignancy among patients
with dermatomyositis, but that the proof of a definite statistical
significance remained precluded by the lack of large and controlled
series. In addition, all the studies or reviews published before 1975 can
be largely criticized for a lack of predefined criteria for dermatomyositis.
In 1977, Bohan et al [3] reported the first series of patients with
dermatomyositis and polymyositis selected according to their own
diagnostic criteria. They found that malignancy occurred in 13 (eight
with dermatomyositis, five with polymyositis) of the 153 studied patients,
i.e., 8.5%. However, their study did not allow them to draw any definite
conclusions about a significant increase of malignancy among patients
with dermatomyositis because of a lack of control group from the general
population and a high number of patients with an overlap syndrome.
During the next 12 years, many authors, by using systematically the
diagnostic criteria of Bohan and Peter, have attempted to settle this
question. Table I summarizes the data drawn from the main studies in
that recent era. The strategies employed were far from being homo-
geneous. Most were retrospective series with an analysis of records from
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patients with dermatomyositis or polymyositis registered in a single
department or institution [3–6,8–10,12,16] over a 5- to 19-year period
(average, 11 years). Some were multicenter [15] or national [7,13,14,17]
retrospective series made over a 2- to 20-year period (average, 9 years)
with an analysis of data registered from a questionnaire. In these studies,
the diagnostic methods used both for dermatomyositis/polymyositis and
malignancy were not totally uniform, leading to heterogeneity of the
patients studied, especially when the period of recruitment exceeded 10
years [3,4,6,7,8,10,15,16]. Despite this, these recent studies have
contributed to answering some of the questions about the relationship
between dermatomyositis and malignancy.
Is there a significant increase of cancers in patients with dermato-
myositis when compared to an age- and sex-matched general popula-
tion? Only two reports applying the rigorous diagnostic criteria as defined
by Bohan and Peter include a control group of comparably assessed
patients in order to clearly demonstrate an association between
dermatomyositis and malignancy [6,10]. Using standard case-control
and cohort analysis methods, Manchul et al [6] have compared the
frequency of malignant neoplasms in 71 patients with dermatomyositis or
polymyositis with age- and sex-matched control groups suffering from
other rheumatic and musculoskeletal disorders. They have found a
significant increase in frequency of malignant diseases in dermatomyo-
sitis (32%) as compared with a control group (9%); however they were
largely of malignant neoplasms discovered at or before the time of
diagnosis of dermatomyositis. The cohort analysis did not show any
increase in the number of subsequent neoplasms in patients with
dermatomyositis. In another case-control study of 115 patients (50
dermatomyositis, 65 polymyositis), Lakhanpal et al [10] did not
demonstrate any difference in the incidence of malignancy between
patients with dermatomyositis (22%) and controls (17%). However, the
results of this study are questionable because of the surprisingly high
prevalence of cancer in the control group and a possible geographical
referral bias. Lastly, using case-control methods in a nationwide survey
over a 2-year period, Lyon et al [14] have analyzed the data of 104 cases
suffering from dermatomyositis/polymyositis and of sex-matched sibling
controls. They did not find a significant association between malignant
disease and a risk of dermatomyositis/polymyositis. But these results are
difficult to interpret because of the choice of controls and the absence of
a clear discrimination between dermatomyositis and polymyositis. Thus,
to date, only one study [6] using the standard diagnostic criteria and the
classification of Bohan and Peter as well as case-control methods has
demonstrated an excess of malignancy incidence among patients with
dermatomyositis when compared with controls without myositis.
Is there a significant increase of cancer in patients with dermato-
myositis when compared to polymyositis? A higher frequency of
malignancy in dermatomyositis patients (26%) versus polymyositis
patients (3%) has been found by Callen et al [4]. However, all the
subsequently published series were not able to demonstrate a statistically
significant difference in the incidence of malignancy between dermato-
myositis and polymyositis [5–12]. Cumulative data from recent series
including both dermatomyositis and polymyositis patients [3–12]
(summarized in Table I) give an average frequency of malignancy of
18% (70/382; range, 6–32%) in dermatomyositis and of 14% (52/360;
range, 0–28%) in polymyositis, a difference that is not statistically
significant. In contrast, most recent studies [13,15–17], including only
patients with dermatomyositis, show a higher average frequency of
malignancy (243/772, i.e., 31%; range, 30–43%). One of the reasons for
this variation might be a difference in the referral pattern, because series
issued from a dermatologic recruitment, which generally do not include
patients with polymyositis, show the highest prevalence of malignancy
among patients with dermatomyositis [4,13,15–17]. Therefore, it appears
that the idea of an increased frequency of malignancy in dermatomyositis
as compared to polymyositis still remains a ‘‘fiction,’’ as stated by Peter
and Bohan [3] in the conclusions of their paper in 1977, which still has to
be demonstrated in future prospective studies.
In summary, despite epidemiologic data accumulated in recent years,
a controversy remains about the reality of a significant association
between dermatomyositis and malignancy. Ideally, what is now needed
is 1) a large, multicenter prospective study; 2) with strict criteria for
inclusion of patients that differentiate dermatomyositis from polymyositis;
3) using case-control methods with age- and sex-matched control groups
to determine if patients with cancer are at an increased risk of
Table I. Recent Studies on Dermatomyositis and Malignancy
Frequency of Malignancy
Author (year) Designa Dermatomyositis Polymyositis Controls
Bohan (1977) Re, In 8/60 (13%) 5/50 (10%) —
Callen (1980) Re, In 7/27 (26%) 1/31 (3%) —
Henriksson (1982) Re, In 3/50 (6%) 4/20 (20%) —
Manchul (1985) Re, In, C, Co 10/31 (32%) 7/40 (17%) 4/42 (9%)
Benbassat (1985) Re, Mu 10/39 (26%) 3/21 (14%) —
Tymms (1985) Re, Inb 7/36 (19%) 9/69 (13%) —
Holden (1985) Re, Inb 4/26 (15%) 0/10 (0%) —
Lakhanpal (1986) Re, In, C 11/50(22%) 18/65 (28%) 20/115 (17%)
Ponge (1986) Re, In 7/39 (18%) 2/20 (10%) —
Hochberg (1986) Re, In 3/24 (12%) 3/34 (9%) —
Hidano (1986) Re, Mu 171/569 (30%) — —
Cox (1990) Re, Mu 23/53 (43%) — —
Basset-Seguin (1990) Re, In 13/32 (40%) — —
Bonnetblanc (1990) Re, Mu 36/118(30%) — —
aRe, retrospective; In, from a single institute; Mu, multicenter; C, case-control study; Co, cohort analysis.
bStudy also included children.
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dermatomyositis (or polymyositis); 4) using cohort analysis with age- and
sex-matched control groups to determine if dermatomyositis (or
polymyositis) increases the risk of cancer.
Clinical and Laboratory Aspects In her review of the literature, Barnes [2]
stated that patients with dermatomyositis and malignancy tended to be
older than the general dermatomyositis population. Although this feature
is not always statistically demonstrated in other series [4,10,11], several
subsequent studies have confirmed that the frequency of malignancy in
patients with dermatomyositis increases with age [7,8,15–17]. In contrast,
malignant disease is not seen in childhood dermatomyositis [3,9,13,23].
It is now established that malignancy occurs in a nearly equal number of
men and women with dermatomyositis and that this sex ratio is similar to
the one encountered in patients suffering from dermatomyositis/
polymyositis [2–4,6,10,11]. Several reports have emphasized that no
clinical differences were found between patients with dermatomyositis
who had a malignant neoplasm and those who did not [2,3,9–11]. In a
recent paper, Basset-Seguin et al [16] have attempted to identify potential
predictive signs of associated malignancy in a well-defined group of 32
adult patients with dermatomyositis. They have found that cutaneous
necrosis and an elevated sedimentation rate (30 and 54%, respectively)
were more frequent in patients with an underlying malignancy. In a large
multicenter study, Bonnetblanc et al [17] found a greater association with
cancer in the cases of dermatomyositis of acute onset (30 versus 16% in
the subacute onset group). However, from a practical point of view, the
search for such predictive signs is of limited interest since they are far
from being constantly present in the cases with underlying malignancy.
In contrast, it is widely accepted that the presence of an associated
malignancy is a major indicator of a poor prognosis in dermatomyositis
[3,4,7,11,13,24]. On the other hand, the prognosis is similar in cases
of dermatomyositis and polymyositis without associated malignancy
[7,25]. Finally, the frequency and distribution of abnormalities in muscle
biopsy specimens are not significantly different in dermatomyositis with
or without malignancy. In particular, necrotic changes are variably
encountered in dermatomyositis patients with associated malignancy
[11,12,16].
Types of Tumors Although these results are often based on the collection
of reported cases from the literature [2,25], the types of neoplasms found
in association with dermatomyositis seem to parallel those observed in
the general population [4,10,13,16,17]. In the study by Lakhanpal et al
[10], the overall distribution of types of cancers was not significantly
different in patients and controls. Carcinomas of the lung, stomach,
ovary, and breast are commonly seen in dermatomyositis. The high
frequency of gynecologic tumors (especially carcinoma of the ovary) in
dermatomyositis has been noted in several studies [2,15,26] and poses
essentially a practical problem (see below). Other malignant diseases
have also been described, such as lymphoma [8,10,12,13], Hodgkin’s
disease [8,27], myeloma [27], or thymoma [13], that generally involve
immunologic disturbances. Lastly, the association of nasopharyngeal
carcinoma with dermatomyositis in China may reflect the geographical
and/or ethnic prevalence of this tumor [28].
Temporal Relationship The temporal relationship between the onset of
dermatomyositis and the diagnosis of malignancy is quite variable,
although Barnes [2] has stated that in most cases tumor and myositis
both occur within a relatively short period of time of one another.
The malignancy can precede, occur concurrently with, or follow the
diagnosis of dermatomyositis [4,13,17]. However, the mode of the
association dermatomyositis-cancer must be considered. The paraneo-
plastic course (i.e., the disappearance of both skin and muscular signs
after treatment of the tumor and the recurrence with further metastasis) of
many previously reported cases of dermatomyositis must be underlined
[13,17,22,29]. On the other hand, malignant disease precedes or occurs
concurrently with dermatomyositis in 65 to 82% of cases [2,4,13,17,24].
In that instance, malignancy may be a risk factor or a triggering event for
the development of dermatomyositis. Conversely, the fact that cancer
may also follow the dermatomyositis raises the question of whether
dermatomyositis (or polymyositis) increases the risk of cancer. The role of
the treatment of dermatomyositis should be questioned in case of late-
occurring tumors, especially when immunosuppressive drugs have been
used. Such questions will be partly solved when adequate prospective
epidemiologic studies (see above) become available.
MALIGNANCY EVALUATION IN THE
DERMATOMYOSITIS PATIENT
For years, the value of an extensive and non-directed search for
malignancy in patients with dermatomyositis has been questioned
[1,3,4,25,27,30,31]. In 1977, Bohan et al [3] concluded that a thorough
evaluation for occult malignancy in all patients with dermatomyositis or
polymyositis was only ‘‘fancy’’ because the true frequency of malignant
disease in these disorders had not been determined. Fourteen years later,
this statement remains largely true. Extensive investigations for malig-
nancy in the absence of abnormal clinical findings appear unjustified for
the following reasons: 1) in the majority of cases, malignancy is
discovered on the basis of clinical signs, symptoms, or routine screening
laboratory tests [4,15,17,25]; 2) the poor yield from blind-screening
radiologic investigations [30]; 3) the absence of a large, prospective,
cohort study determining the usefulness and the optimal screening
policies for malignant diseases; and 4) the uncertainty that still exists
about a true association between dermatomyositis/polymyositis and
malignancy. On the other hand, some authors have reported anecdotal
cases of patients with myositis in whom nondirected tumor searches have
resulted in the discovery of an underlying malignancy [6,10,32,33].
However, ovarian cancer represents a particular problem because it is
very difficult to diagnose early [15], and, therefore, a systematic pelvic
examination has been suggested [15,26,34].
In summary, the question of the extent of the search for malignancy in
a patient presenting with dermatomyositis has not yet been resolved and
remains controversial. From our present knowledge, a reasonable
medical work-up in patients with dermatomyositis, as recently suggested
by Cox et al [15] and Richardson and Callen [35], should include 1) a
complete medical history with review of the different systems and a
physical examination including a rectal, pelvic, and breast examination;
2) a complete blood count, routine serum chemistry analysis, serum
protein electrophoresis, multiple stool guaiacs, and urinalysis; 3) a chest
X-ray radiograph; 4) a mammography (in women). In addition, any
abnormality in these screening tests should be investigated further, and
more extensive investigations should be performed in patients who have
suffered from a previous malignancy, and in those who respond poorly to
treatment or who present with an unexplained flare of myositis [15,35].
IS THERE A COMMON BIOLOGIC DEFECT THAT
EXPLAINS THE OCCURRENCE OF BOTH DISORDERS?
If one accepts that the association between dermatomyositis and
malignancy is not fortuitous, it is tempting to suggest that both disorders
share a common biologic defect. Although the pathogenetic mechanisms
of dermatomyositis and polymyositis are still largely conjectural, they
may involve genetic and environmental factors together with cellular and
humoral immunologic abnormalities. As in some other types of
autoimmune disorders, dermatomyositis and polymyositis show a strong
association with human leukocyte antigens (HLA), with an increased
incidence of HLA-DR3 and HLA-B8 [36,37]. However, this has been
essentially found in juvenile dermatomyositis [37], which is not
associated with malignancy and, to date, studies on a possible
association between class II or class I HLA antigens, adult dermatomyo-
sitis, and malignancy are still lacking.
Among the numerous environmental factors like toxins, drugs,
infections and, vaccinations that may play an important role in the
development of dermatomyositis, a viral etiology remains the most likely
candidate. For example, there is an increased incidence of antibodies to
coxsackie B in both adult and juvenile dermatomyositis [38,39]. RNA
fragments of this virus have been found by in situ hybridization in the
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muscles of patients with dermatomyositis and polymyositis [40]. It has
also been suggested that antibodies to histidyl-tRNA synthetase (Jo-1
antigen), which are present in 20–30% of dermatomyositis and
polymyositis, arise as a result of the immunization against picornaviruses
[41]. Although viruses may be an important trigger factor in a subset of
dermatomyositis/polymyositis patients, a pathogenic link with malig-
nancy (for example, involving oncogens) remains yet to be established.
There is much evidence for abnormalities involving both the cellular and
humoral immunity in the pathogenesis of dermatomyositis and poly-
myositis. Abnormalities of the humoral immunity (reviewed in the paper
of Targoff et al in this issue) include immunoglobulin and complement
deposition in muscle and skin biopsies, circulating immune complexes,
hyper-, hypo-, or agammaglobulinemia, and the presence of numerous
circulating autoantibodies, both specific and nonspecific for myositis
[36]. However, no relationship has been demonstrated between any of
these autoantibodies and the presence of an underlying cancer. The
cellular immune abnormalities include the presence of activated mono-
nuclear cells in skeletal muscle, abnormal mononuclear cell trafficking to
muscle, altered peripheral mononuclear cell phenotypes, decreased
autologous mixed lymphocyte responses, and mitogenic responses and
proliferative responses to autologous muscle [36]. Recent studies of the
inflammatory infiltrates in muscles also suggest that activated lympho-
cytes, especially T cells, play a major role [42–45]. The phenotypes of the
infiltrating T cells may vary according to their location in the muscular
tissue or the subsets of patients with myositis [43], and may be organ-
specific [46]. Cellular immunity abnormalities may provide a possible
link between dermatomyositis and malignancy because delayed-hyper-
sensitivity to tumor extracts has been observed in some patients whose
myositis was associated with malignancy [47]. On the other hand, it has
been hypothesized that, in dermatomyositis and polymyositis, alterations
of the cellular immunity result in a decreased ability to eliminate the
neoplastic cells [35]. However, epidemiologic data do not support that
dermatomyositis might be a risk factor for the subsequent development of
malignancy. In summary, a possible pathogenic link remains largely
hypothetical and further studies are necessary to demonstrate a
connection at a biologic level between dermatomyositis and an
underlying malignancy.
CONCLUSION
The question of the association of dermatomyositis and malignancy
reflects the history of medicine, based upon observations whose
accumulation has overemphasized the truth. Also, due to historical data,
physicians are sometimes obsessed by the fear of misdiagnosing a cancer
in patients suffering from dermatomyositis. However, analyses of large
but retrospective series published since the pioneering work of Bohan
and Peter have not been able to settle the matter. Until basic research
may provide a possible connection between the two disorders,
prospective epidemiologic studies using the case-control methods and
cohort analysis remain the best way to rigorously demonstrate the reality
and to study the nature of the association between dermatomyositis and
malignancy. In addition, such studies may help to clarify the optimal
screening strategies for malignant neoplasms in patients with dermato-
myositis, which is necessary for both ethical and financial reasons.
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